Set up on the Genopole® campus in Evry, the CNG, managed by Mark Lathrop, enjoys an exceptional research location due to its proximity to and relations with the other laboratories on the site.

This national resource center was created in October of 1998 with the objective of developing and applying gene typing (characterization of the differences existing between individuals, called "polymorphism") and the technologies linked to this activity. One of its major focuses is identifying genes involved in hereditary diseases.

The CNG offers state-of-the-art processes, which meet high-speed gene typing required for the development of innovative and integrated technologies.

The activities of the CNG are grouped into three categories: projects linked to the development of the technological platform, scientific projects responding to calls for tenders and initiated by external teams (hosting or external collaborations), and scientific projects initiated by the CNG (notably, pilot projects).

The scientific and technological resources are made available to academic teams through collaborations in order to allow them to carry out large-scale research programs, and notably in determining genetic factors causing diseases having a major impact on public health.
Studies in progress include: autoimmune diseases (type 1 diabetes, thyroid diseases, acute systemic Lupus Erythematosus, asthma, psoriasis), cardio-vascular diseases (myocardial infarction, cerebrovascular accidents, hypertension), infectious diseases (malaria, AIDS), cancer (loss of heterozygoty, genetic predisposition to lung cancer), monogenic disorders (monogenic types of diabetes, deafness, dermatological disorders, muscular dystrophies, kidney diseases, etc.).
Setting up scientific collaborations among the scientific members of the Evry site is the condition necessary for the development of a true genomic campus in Evry. Since July of 1999, when the CNG became fully operational, the center has established numerous partnerships in specific scientific programs with the CNS, Génoplante/NRA, Aventis/INSERM, Généthon/AFM (psoriasis study; genetic studies in French Polynesia being prepared), and AFM/Corbeil-Essonne Hospital (diabetic complication studies) as well as wide-range of international co-operation.

For more information
CNG's web site.